Program
brexpiprazole
Also written as “Brexpiprazole”, “OPC-34712” and “Brexpiprazole (OPC-34712)”.
Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Stress Disorders, Post-Traumatic · Alzheimer Disease · Mania, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 600 open or running | phase 4since Mar 29, 2021 | Nov 24, 2008 | none ahead |
| H. Lundbeck | 90 open or running | phase 3since Mar 11, 2013 | Mar 11, 2013 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Dec 4, 2025 | Dec 4, 2025 | none ahead |
Also a collaborator on its studies: quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 42 studies since Jul 11, 2011.
- May 7, 2018Phase 3 study in Alzheimer DiseaseOtsuka · NCT03548584 · 345 enrolled · United States
- Jul 11, 20183 phase 3 studiesOtsuka · NCT03594123, NCT03697603, NCT03737474
- Aug 5, 2018Phase 3 study in Agitation Associated With Dementia of the Alzheimer's TypeOtsuka · NCT03620981 · 410 enrolled · Japan
- Oct 28, 2018Phase 3 study in Agitation Associated With Dementia of the Alzheimer's TypeOtsuka · NCT03724942 · 164 enrolled · Japan
- Nov 2, 20182 phase 1 studiesOtsuka · NCT03734354, NCT03734302
- Mar 12, 2019Phase 3 study in SchizophreniaOtsuka · NCT03874494 · 371 enrolled · China
- Sep 20, 2019Phase 2 study in Borderline Personality DisorderOtsuka · NCT04100096 · 332 enrolled · United States, Spain, Ukraine
- Oct 10, 2019Phase 3 study in Stress Disorders, Post-TraumaticOtsuka · NCT04124614 · 450 enrolled · United States
- Nov 20, 20192 phase 3 studiesOtsuka · NCT04174365, NCT04174170
- Dec 2, 2019Phase 3 study in Borderline Personality DisorderOtsuka · NCT04186403 · 201 enrolled · United States
- Feb 4, 2020Phase 3 study in Autistic DisorderOtsuka · NCT04258839 · 95 enrolled · United States
- Mar 29, 2021Phase 4 study in Depressive Disorder, MajorOtsuka · NCT04830215 · 122 enrolled · Canada
- May 31, 2022Phase 4 study in Depressive Disorder, MajorOtsuka · NCT05504486
- Dec 4, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in SchizophreniaNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07266792 · 36 enrolled · India
TargetBeta
“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
Studies
The newest 60 of 70 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07266792Schizophrenia · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Aug 4, 2025 | 36 |
| NCT05504486Depressive Disorder, Major | 4 | Withdrawn | Otsuka | Mar 22, 2023 | 0 |
| NCT04830215Depressive Disorder, Major · Canada | 4 | Completed | Otsuka | May 27, 2022 | 122 |
| NCT04258839Autistic Disorder · United States | 3 | Completed | Otsuka | Mar 16, 2023 | 95 |
| NCT04186403Borderline Personality Disorder · United States | 3 | Completed | Otsuka | Sep 22, 2021 | 201 |
| NCT04174170Stress Disorders, Post-Traumatic · United States | 3 | Completed | Otsuka | Jul 25, 2023 | 591 |
| NCT04174365Autistic Disorder · United States | 3 | Completed | Otsuka | Aug 8, 2022 | 119 |
| NCT04124614Stress Disorders, Post-Traumatic · United States | 3 | Completed | Otsuka | Jul 19, 2023 | 450 |
| NCT04100096Borderline Personality Disorder · United States, Spain, Ukraine | 2 | Completed | Otsuka | Jun 27, 2021 | 332 |
| NCT03874494Schizophrenia · China | 3 | Completed | Otsuka | Aug 6, 2021 | 371 |
| NCT03734354Health · China | 1 | Completed | Otsuka | May 18, 2020 | 30 |
| NCT03734302Healthy · China | 1 | Completed | Otsuka | Jun 10, 2020 | 10 |
| NCT03724942Agitation Associated With Dementia of the Alzheimer's Type · Japan | 3 | Completed | Otsuka | Dec 2, 2021 | 164 |
| NCT03620981Agitation Associated With Dementia of the Alzheimer's Type · Japan | 3 | Completed | Otsuka | Apr 21, 2023 | 410 |
| NCT03737474Depressive Disorder, Major · Japan | 3 | Completed | Otsuka | Mar 17, 2021 | 248 |
| NCT03697603Depressive Disorder, Major · Japan | 3 | Completed | Otsuka | Jun 6, 2022 | 740 |
| NCT03594123Alzheimer Disease · United States | 3 | Completed | Otsuka | Sep 19, 2022 | 259 |
| NCT03548584Alzheimer Disease · United States | 3 | Completed | Otsuka | May 23, 2022 | 345 |
| NCT03538691Depressive Disorder, Major · United States | 3 | Completed | Otsuka | Jul 8, 2022 | 1,149 |
| NCT03487198Depressive Disorder, Major · China | 3 | Terminated | Otsuka | May 30, 2019 | 65 |
| NCT03292848Attention Deficit Disorder with Hyperactivity · United States | 1 | Completed | Otsuka | May 21, 2018 | 24 |
| NCT03287869Mania · United States, Bulgaria, Croatia and more | 3 | Completed | Otsuka | Jul 31, 2019 | 381 |
| NCT03259555Mania · United States, Bulgaria, Poland and more | 3 | Completed | Otsuka | Jan 2, 2019 | 322 |
| NCT03257865Mania · United States, Croatia, Ukraine | 3 | Completed | Otsuka | Jan 22, 2019 | 333 |
| NCT03238326Schizophrenia · United States, France, Italy and more | 3 | Completed | Otsuka | Apr 22, 2025 | 295 |
| NCT03198078Schizophrenia · United States | 3 | Completed | Otsuka | Apr 3, 2023 | 316 |
| NCT03033069Stress Disorders, Post-Traumatic · United States | 2 | Completed | Otsuka | Nov 12, 2018 | 336 |
| NCT02968121Schizophrenia · United States | 1 | Terminated | Otsuka | Dec 14, 2017 | 22 |
| NCT02875080Healthy Adult Male · Japan | 1 | Completed | Otsuka | Nov 27, 2016 | 18 |
| NCT02758067Schizophrenia | 3 | Withdrawn | H. Lundbeck | Jun 2016 | 0 |
| NCT02212613Depressive Disorder, Major · United States | 3 | Withdrawn | Otsuka | Nov 2015 | 0 |
| NCT02196506Depressive Disorder · United States, Germany, Hungary and more | 3 | Completed | Otsuka | Apr 2016 | 837 |
| NCT02194933Schizophrenia · United States | 3 | Completed | Otsuka | Apr 2016 | 38 |
| NCT02411695Schizophrenia · United States | 1 | Completed | Otsuka | Jan 1, 2017 | 43 |
| NCT02054702Schizophrenia | 3 | Completed | Otsuka | Jun 2014 | 97 |
| NCT02013622Schizophrenia · United States | 3 | Completed | Otsuka | Sep 2014 | 49 |
| NCT02013609Schizophrenia · United States | 3 | Completed | Otsuka | Sep 2014 | 48 |
| NCT02013531Depressive Disorder, Major · United States | 3 | Completed | Otsuka | May 2014 | 37 |
| NCT02012218Depressive Disorder, Major · United States | 3 | Completed | Otsuka | Oct 2014 | 61 |
| NCT01987960Stress Disorders, Post-Traumatic · United States, Estonia, Finland and more | 3 | Terminated | H. Lundbeck | Oct 2015 | 417 |
| NCT01944969Depressive Disorder, Major · United States | 3 | Terminated | H. Lundbeck | May 2014 | 26 |
| NCT01942785Depressive Disorder, Major · United States | 3 | Completed | H. Lundbeck | Jul 2014 | 55 |
| NCT01942733Parasomnias | 3 | Completed | H. Lundbeck | Aug 2014 | 44 |
| NCT01922258Alzheimer Disease · United States, Bulgaria, Canada and more | 3 | Completed | Otsuka | Mar 2017 | 270 |
| NCT01862640Alzheimer Disease · United States, Croatia, Germany and more | 3 | Completed | Otsuka | Mar 15, 2017 | 433 |
| NCT01854944Schizophrenia · United States | 1 | Completed | Otsuka | Jul 2014 | 12 |
| NCT01838681Depressive Disorder, Major · United States, Bulgaria, Canada and more | 3 | Completed | H. Lundbeck | Jun 2016 | 1,986 |
| NCT01837797Depressive Disorder, Major · United States | 3 | Terminated | H. Lundbeck | May 2014 | 129 |
| NCT01810783Schizophrenia · United States, Estonia, Poland and more | 3 | Completed | H. Lundbeck | Dec 2015 | 210 |
| NCT01810380Schizophrenia · United States | 3 | Completed | H. Lundbeck | Dec 2014 | 468 |
| NCT01727726Depressive Disorder · United States, Canada, France and more | 3 | Completed | Otsuka | Oct 17, 2016 | 2,182 |
| NCT01668797Acute Schizophrenia · United States, Colombia, Malaysia and more | 3 | Completed | Otsuka | Jan 2015 | 524 |
| NCT01670279Depressive Disorder, Major · United States | 1 | Completed | Otsuka | May 2013 | 18 |
| NCT01649557Schizophrenia · United States, Bulgaria, Croatia and more | 2 | Completed | Otsuka | Aug 2011 | 244 |
| NCT01456897Schizophrenia · Japan | 3 | Completed | Otsuka | May 2015 | 282 |
| NCT01451164Schizophrenia · Japan | 3 | Completed | Otsuka | Jun 2015 | 459 |
| NCT01447576Depressive Disorder, Major · United States | 2 | Completed | Otsuka | Dec 2012 | 1,036 |
| NCT01423916Schizophrenia · United States | 1 | Completed | Otsuka | Feb 2012 | 218 |
| NCT01397786Schizophrenia · United States, Canada, Colombia and more | 3 | Completed | Otsuka | Jan 2016 | 1,044 |
| NCT01396421Acute Schizophrenia · United States, Canada, Japan and more | 3 | Completed | Otsuka | Jan 2014 | 636 |
How it is read
Names in the registry
- “Brexpiprazole”, 44 entries
- “OPC-34712”, 17 entries
- “Brexpiprazole (OPC-34712)”, 2 entries
- “Brexpiprazole, OPC-34712”, 2 entries
- “OPC-34712 + ADT”, 2 entries
Codes read as this program: OPDC34712.
Conditions, from the studies’ own filings
- Schizophrenia, 26 studies
- Depressive Disorder, Major, 21 studies
- Stress Disorders, Post-Traumatic, 4 studies
- Alzheimer Disease, 4 studies
- Mania, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.